Kelun-Biotech has positioned 30+ oncology candidates for clinical advancement, establishing the Chinese firm as a significant competitor in the antibody-drug conjugate race against established pharmaceutical players.1 The pipeline concentration sets up a competitive approval cycle through 2027 that will likely reshape biotech valuations in the oncology sector.
Pfizer, Regeneron, and BioNTech are simultaneously pushing targeted therapies through late-stage trials. BioNTech is advancing differentiated treatment approaches across lung cancer settings, including pumitamig, gotistobart, and a HER3-targeted ADC.2 Regeneron's Dupixent, a fully human monoclonal antibody inhibiting IL-4 and IL-13 pathway signaling, received approval in Japan for bullous pemphigoid treatment.3
The ADC platform has become a focal point for pipeline investment. These conjugates combine targeted antibody delivery with cytotoxic payloads, offering precision oncology approaches that command premium valuations. Kelun-Biotech's 30+ candidate pipeline suggests aggressive capital deployment into this mechanism class.
Smaller biotechs are also entering late-stage trials in high-need oncology segments. Silexion Therapeutics received Israeli Ministry of Health approval for a Phase 2/3 trial of SIL204 in locally advanced pancreatic cancer, targeting KRAS mutations present in over 90% of pancreatic cancers.4 The company's earlier Phase 2a trial of predecessor treatment Loder showed positive trends versus chemotherapy alone.5
The clustering of regulatory submissions in 2026-2027 creates both opportunity and risk for investors. Companies reaching approval first in specific indications may capture market share before competitors launch. However, the crowded pipeline also raises the bar for differentiation and could compress pricing power if multiple therapies target similar patient populations.
Pipeline velocity has become a critical valuation metric. Biotechs demonstrating clinical progress across multiple candidates simultaneously—like Kelun-Biotech's 30+ programs—may command premiums over single-asset developers. The regulatory bottleneck ahead will test which platforms can execute at scale while maintaining safety and efficacy standards.
